Patent intelligence · WO
WO 03007994
SCHILDDRÜSENTHERAPEUTIKA
SCHILDDRÜSENTHERAPEUTIKA
Patent details — WO 03007994
- Jurisdiction
- WO
- Status
- expired
- Grant date
- Jan 30, 2003
- Expiration
- Jan 25, 2023
- Applicant
- BERLIN CHEMIE AG [DE]
- CPC classes
- A61K 9/ 20 A I, A61K 31/ 198 A I, A61K/31198, A61K/92013
Quick answer
WO 03007994 (SCHILDDRÜSENTHERAPEUTIKA) is held by BERLIN CHEMIE AG [DE]. Status: expired. Granted Jan 30, 2003. Expires Jan 25, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BERLIN CHEMIE AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 20 A I, A61K 31/ 198 A I, A61K/31198, A61K/92013, A61K/92018, A61K/92054
More from BERLIN CHEMIE AG [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2024252263
COMPOSITIONS SOLIDES DE DICHLORHYDRATE D'ÉLACESTRANT, LEURS PROCÉDÉS DE FABRICATION ET MÉTHODES DE TRAITEMENT LES UTILISANT
granted -
WO 2024023766
POLYTHÉRAPIE À BASE D'INHIBITEUR DE P13K
granted -
CA 3259243
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE BCL-2
granted -
CA 3259252
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE FLT3
granted -
WO 2022029639
FORMULATIONS PHARMACEUTIQUES AMÉLIORÉES COMPRENANT DES INHIBITEURS DE PI3K
granted -
US 2021015826
ANTICANCER PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
granted -
US 2020040086
PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY
granted -
CA 3102476
ASSOCIATIONS PHARMACEUTIQUES
granted
Frequently asked questions
What is US patent 03007994?
WO 03007994 (SCHILDDRÜSENTHERAPEUTIKA) is held by BERLIN CHEMIE AG [DE]. Status: expired. Granted Jan 30, 2003. Expires Jan 25, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 03007994?
BERLIN CHEMIE AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 03007994 expire?
Our index shows an expiration date of Jan 25, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.